Study S003276

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Center Study to Evaluate the Efficacy, Safety, and Tolerability of CT-868 Administered for 26 Weeks to Overweight and Obese Participants With Type 2 Diabetes Mellitus

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT05110846
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 103
Start: 2022-02-22
Primary completion: 2023-02-28
Lead sponsor: Carmot Therapeutics, Inc.
Conditions: Obesity; Overweight; Type 2 Diabetes Mellitus
Interventions: DRUG:Placebo; DRUG:CT-868
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:BP45664

Registered primary outcomes

Change from Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 26 [Baseline and Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.